Avigan DE - Search Results

1

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell EK, Raje N, Cook D, Yee AJ, Logan E, Avigan DE, Jakubowiak A, Shaw K, Daley H, Nikiforow S, Griffin F, Cornwell C, Shen A, Heery C, Maus MV. Frigault MJ, et al. Among authors: avigan de. Blood Adv. 2023 Mar 14;7(5):768-777. doi: 10.1182/bloodadvances.2022007210. Blood Adv. 2023. PMID: 35468618 Free PMC article. Clinical Trial.

2

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.

Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, Anderson KC. Raje N, et al. Blood. 1999 Mar 1;93(5):1487-95. Blood. 1999. PMID: 10029575 Free article.

3

Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.

Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D. Gong J, et al. Blood. 2002 Apr 1;99(7):2512-7. doi: 10.1182/blood.v99.7.2512. Blood. 2002. PMID: 11895787 Free article.

4

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.

Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC. Raje N, et al. Br J Haematol. 2004 May;125(3):343-52. doi: 10.1111/j.1365-2141.2004.04929.x. Br J Haematol. 2004. PMID: 15086415 Free article.

5

Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.

Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, Avigan D. Vasir B, et al. Br J Haematol. 2005 Jun;129(5):687-700. doi: 10.1111/j.1365-2141.2005.05507.x. Br J Haematol. 2005. PMID: 15916692 Free article.

6

Dendritic cell fusion vaccines for cancer immunotherapy.

Rosenblatt J, Kufe D, Avigan D. Rosenblatt J, et al. Expert Opin Biol Ther. 2005 May;5(5):703-15. doi: 10.1517/14712598.5.5.703. Expert Opin Biol Ther. 2005. PMID: 15934845 Review.

7

Can leukemia-derived dendritic cells generate antileukemia immunity?

Rosenblatt J, Avigan D. Rosenblatt J, et al. Expert Rev Vaccines. 2006 Aug;5(4):467-72. doi: 10.1586/14760584.5.4.467. Expert Rev Vaccines. 2006. PMID: 16989627 Free article. Review.

8

MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.

Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, Stone R, Kufe D. Kawano T, et al. Cancer Res. 2007 Dec 15;67(24):11576-84. doi: 10.1158/0008-5472.CAN-07-2756. Cancer Res. 2007. PMID: 18089786 Free PMC article.

9

PML targeting eradicates quiescent leukaemia-initiating cells.

Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP. Ito K, et al. Among authors: avigan de. Nature. 2008 Jun 19;453(7198):1072-8. doi: 10.1038/nature07016. Epub 2008 May 11. Nature. 2008. PMID: 18469801 Free PMC article.

10

Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.

Vasir B, Wu Z, Crawford K, Rosenblatt J, Zarwan C, Bissonnette A, Kufe D, Avigan D. Vasir B, et al. J Immunol. 2008 Jul 1;181(1):808-21. doi: 10.4049/jimmunol.181.1.808. J Immunol. 2008. PMID: 18566447 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters